Cytrx Corp (OTC:CYTR)

CytRx Corporation as (CytRx), incorporated in 1985, is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology. Its drug development pipeline includes clinical development of three product candidates for cancer indications, including Phase 2 clinical trials with bafetinib in patients hormone-refractory prostate cancer and relapsed or refractory B-cell chronic lymphocytic (B-CLL) leukemia, an additional planned pharmacokinetic clinical trial with bafetinib in patients with brain cancer, two planned Phase 2 clinical trials for INNO-206 as a treatment for soft tissue sarcomas and pancreatic cancer following an abbreviated safety trial, and clinical trials with tamibarotene for the treatment of non-small-cell lung cancer and acute promyelocytic leukemia (APL). It has two drug candidates based on its molecular chaperone regulation technology, which are designed to repair or degrade mis-folded proteins associated with disease.

Web site: http://www.cytrx.com

Last updated July 30, 2012